Which has better valuation & earnings, MRNA or NVAX?

Novavax has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 30.57 -$2.82B -$7.99 N/A Novavax $413.80M 4.12 $440.30M -$1.52 N/A

Is MRNA or NVAX more profitable?

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Novavax -59.87% -14.82% -13.35%

Does the media favor MRNA or NVAX?

In the previous week, Moderna had 62 more articles in the media than Novavax. MarketBeat recorded 91 mentions for Moderna and 29 mentions for Novavax. Moderna's average media sentiment score of 0.57 beat Novavax's score of 0.21 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 39 Very Positive mention(s) 15 Positive mention(s) 13 Neutral mention(s) 5 Negative mention(s) 8 Very Negative mention(s) Positive Novavax 4 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NVAX or OCGN?

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $413.80M 4.12 $440.30M -$1.52 N/A Ocugen $4.41M 103.81 -$67.85M -$0.26 N/A

Is NVAX or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Ocugen N/A -127,987.80% -115.95%

Does the media prefer NVAX or OCGN?

In the previous week, Novavax had 22 more articles in the media than Ocugen. MarketBeat recorded 29 mentions for Novavax and 7 mentions for Ocugen. Ocugen's average media sentiment score of 0.66 beat Novavax's score of 0.21 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NVAX or AZN?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $413.80M 4.12 $440.30M -$1.52 N/A Astrazeneca $58.74B 4.35 $10.23B $6.69 24.61

Is NVAX or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to NVAX or AZN?

In the previous week, Novavax had 9 more articles in the media than Astrazeneca. MarketBeat recorded 29 mentions for Novavax and 20 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.46 beat Novavax's score of 0.21 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Astrazeneca 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NVAX or JNJ?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $413.80M 4.12 $440.30M -$1.52 N/A Johnson & Johnson $97.93B 6.86 $26.80B $8.63 32.29

Is NVAX or JNJ more profitable?

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Johnson & Johnson 21.48% 32.42% 13.35%

Does the media prefer NVAX or JNJ?

In the previous week, Johnson & Johnson had 67 more articles in the media than Novavax. MarketBeat recorded 96 mentions for Johnson & Johnson and 29 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.11 beat Novavax's score of 0.21 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 69 Very Positive mention(s) 6 Positive mention(s) 11 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better earnings & valuation, PFE or NVAX?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $63.70B 2.58 $7.77B $0.76 37.92 Novavax $413.80M 4.12 $440.30M -$1.52 N/A

Is PFE or NVAX more profitable?

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Novavax -59.87% -14.82% -13.35%

Does the media prefer PFE or NVAX?

In the previous week, Pfizer had 86 more articles in the media than Novavax. MarketBeat recorded 115 mentions for Pfizer and 29 mentions for Novavax. Pfizer's average media sentiment score of 0.97 beat Novavax's score of 0.21 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 62 Very Positive mention(s) 24 Positive mention(s) 17 Neutral mention(s) 3 Negative mention(s) 6 Very Negative mention(s) Positive Novavax 4 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Novavax (NVAX) Competitors

$10.34 +0.02 (+0.19%)

As of 04:00 PM Eastern

Compare

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you buy Novavax stock or one of its competitors? Novavax's main competitors and comparable companies include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Novavax compare to Moderna?

Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Moderna currently has a consensus price target of $76.72, indicating a potential downside of 48.46%. Novavax has a consensus price target of $14.00, indicating a potential upside of 35.40%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Moderna had 62 more articles in the media than Novavax. MarketBeat recorded 91 mentions for Moderna and 29 mentions for Novavax. Moderna's average media sentiment score of 0.57 beat Novavax's score of 0.21 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	39 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	5 Negative mention(s)	8 Very Negative mention(s)	Positive
Novavax	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Novavax	-59.87%	-14.82%	-13.35%

Novavax has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	30.57	-$2.82B	-$7.99	N/A
Novavax	$413.80M	4.12	$440.30M	-$1.52	N/A

Summary

Novavax beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Novavax (NASDAQ:NVAX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Novavax had 22 more articles in the media than Ocugen. MarketBeat recorded 29 mentions for Novavax and 7 mentions for Ocugen. Ocugen's average media sentiment score of 0.66 beat Novavax's score of 0.21 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.0% of Novavax shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novavax has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market.

Novavax presently has a consensus price target of $14.00, indicating a potential upside of 35.40%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 603.70%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Ocugen	N/A	-127,987.80%	-115.95%

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	4.12	$440.30M	-$1.52	N/A
Ocugen	$4.41M	103.81	-$67.85M	-$0.26	N/A

Summary

Novavax and Ocugen tied by winning 8 of the 16 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Novavax (NASDAQ:NVAX) and Astrazeneca (NYSE:AZN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Novavax had 9 more articles in the media than Astrazeneca. MarketBeat recorded 29 mentions for Novavax and 20 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.46 beat Novavax's score of 0.21 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Astrazeneca	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Novavax presently has a consensus price target of $14.00, suggesting a potential upside of 35.40%. Astrazeneca has a consensus price target of $206.67, suggesting a potential upside of 25.53%. Given Novavax's higher probable upside, research analysts clearly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	4.12	$440.30M	-$1.52	N/A
Astrazeneca	$58.74B	4.35	$10.23B	$6.69	24.61

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Astrazeneca	17.02%	31.45%	13.20%

53.0% of Novavax shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Astrazeneca beats Novavax on 11 of the 16 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Johnson & Johnson	21.48%	32.42%	13.35%

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	4.12	$440.30M	-$1.52	N/A
Johnson & Johnson	$97.93B	6.86	$26.80B	$8.63	32.29

Novavax presently has a consensus target price of $14.00, indicating a potential upside of 35.40%. Johnson & Johnson has a consensus target price of $272.83, indicating a potential downside of 2.09%. Given Novavax's higher possible upside, research analysts clearly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Johnson & Johnson had 67 more articles in the media than Novavax. MarketBeat recorded 96 mentions for Johnson & Johnson and 29 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.11 beat Novavax's score of 0.21 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	69 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Johnson & Johnson beats Novavax on 14 of the 17 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Pfizer (NYSE:PFE) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.70B	2.58	$7.77B	$0.76	37.92
Novavax	$413.80M	4.12	$440.30M	-$1.52	N/A

Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Novavax	-59.87%	-14.82%	-13.35%

In the previous week, Pfizer had 86 more articles in the media than Novavax. MarketBeat recorded 115 mentions for Pfizer and 29 mentions for Novavax. Pfizer's average media sentiment score of 0.97 beat Novavax's score of 0.21 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	62 Very Positive mention(s)	24 Positive mention(s)	17 Neutral mention(s)	3 Negative mention(s)	6 Very Negative mention(s)	Positive
Novavax	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pfizer currently has a consensus price target of $28.28, suggesting a potential downside of 1.88%. Novavax has a consensus price target of $14.00, suggesting a potential upside of 35.40%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Pfizer beats Novavax on 11 of the 17 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.71B	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-6.80	12.72	273.59	25.44
Price / Sales	4.12	1,361.39	675.80	124.32
Price / Cash	2.88	105.29	76.98	52.10
Price / Book	-8.91	16.29	12.89	6.14
Net Income	$440.30M	-$22.72M	$3.47B	$349.01M
7 Day Performance	14.25%	-1.37%	-0.33%	-1.47%
1 Month Performance	39.54%	11.07%	6.51%	2.47%
1 Year Performance	39.73%	53.71%	25.19%	15.84%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	1.9112 of 5 stars	$10.34 +0.2%	$14.00 +35.4%	+36.7%	$1.71B	$413.80M	N/A	1,990
MRNA Moderna	1.4867 of 5 stars	$138.89 -4.3%	$74.31 -46.5%	+523.4%	$55.45B	$2.21B	N/A	4,700	Trending News Analyst Downgrade Insider Trade Options Volume Analyst Revision Gap Down High Trading Volume
OCGN Ocugen	1.8955 of 5 stars	$1.36 -2.2%	$9.50 +598.5%	+28.2%	$461.19M	$4.58M	N/A	80
AZN Astrazeneca	4.6682 of 5 stars	$166.67 +0.4%	$206.67 +24.0%	+0.8%	$257.42B	$61.37B	24.91	96,100	Analyst Revision
JNJ Johnson & Johnson	4.5812 of 5 stars	$273.11 +1.1%	$268.22 -1.8%	+55.0%	$658.18B	$94.19B	31.65	138,200	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors